NCT04241666

Brief Summary

Patients with long-term lower urinary tract dysfunction due to spinal cord injury presenting for a routine urodynamic control will be screened for inclusion and exclusion criteria. Suitable individuals providing written informed consent will undergo renal Doppler sonography and renal scintigraphy in addition to the routine examinations. Conclusions regarding renal function based on the clearance rate determined by scintigraphy (gold standard) will be compared with the conclusions based on Doppler sonography and Cystatin C clearance.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 22, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 27, 2020

Completed
1.9 years until next milestone

Study Start

First participant enrolled

January 5, 2022

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2025

Completed
Last Updated

February 13, 2025

Status Verified

February 1, 2025

Enrollment Period

3 years

First QC Date

January 22, 2020

Last Update Submit

February 11, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • renal clearance

    renal clearance of Technetium-99m-dimercaptosuccinic acid determined by scintigraphy

    at the time of inclusion into study

Secondary Outcomes (5)

  • Cystatin C concentration

    at the time of inclusion into study

  • Cystatin C clearance

    at the time of inclusion into study

  • renal peak systolic velocity

    at the time of inclusion into study

  • renal peak enddiastolic velocity

    at the time of inclusion into study

  • renal resistive index

    at the time of inclusion into study

Other Outcomes (7)

  • size of kidneys

    at the time of inclusion into study

  • renal tissue echogenicity

    at the time of inclusion into study

  • bladder evacuation method

    at the time of inclusion into study

  • +4 more other outcomes

Study Arms (3)

normal renal function

individuals with renal clearance \>89 ml/min/1.73m²

Diagnostic Test: renal scintigraphyDiagnostic Test: renal doppler sonography

mild renal insufficiency

individuals with renal clearance 60-89 ml/min/1.73m²

Diagnostic Test: renal scintigraphyDiagnostic Test: renal doppler sonography

moderate renal insufficiency

individuals with renal clearance 30-59 ml/min/1.73m²

Diagnostic Test: renal scintigraphyDiagnostic Test: renal doppler sonography

Interventions

renal scintigraphyDIAGNOSTIC_TEST

Technetium-99m-dimercaptosuccinic acid scintigraphy of both kidneys

mild renal insufficiencymoderate renal insufficiencynormal renal function

doppler ultrasound of both kidneys

mild renal insufficiencymoderate renal insufficiencynormal renal function

Eligibility Criteria

Age30 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

individuals with long-term lower urinary tract dysfunction due to spinal cord injury

You may qualify if:

  • long-term spinal cord injury (≥10 years)
  • age ≥30 years
  • written informed consent

You may not qualify if:

  • dementia or severe intellectual impairment
  • serious internal illness
  • previous or current tumor disease
  • known allergy to the radioactive marker (Technetium)
  • pregnancy or breastfeeding
  • withdrawal of informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Swiss Paraplegic Centre

Nottwil, Canton of Lucerne, CH-6207, Switzerland

Location

Related Publications (1)

  • Jehli E, Krebs J, Schirp U, Walter MA, Wollner J, Pannek J. Decoding kidney function: evaluating arterial resistive index and cystatin C serum values in individuals with spinal cord injury. World J Urol. 2025 Dec 15;44(1):43. doi: 10.1007/s00345-025-06135-w.

MeSH Terms

Conditions

Spinal Cord InjuriesRenal Insufficiency

Condition Hierarchy (Ancestors)

Spinal Cord DiseasesCentral Nervous System DiseasesNervous System DiseasesTrauma, Nervous SystemWounds and InjuriesKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Officials

  • Jens Wöllner, Dr.

    Swiss Paraplegic Centre

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 22, 2020

First Posted

January 27, 2020

Study Start

January 5, 2022

Primary Completion

December 31, 2024

Study Completion

January 31, 2025

Last Updated

February 13, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

data will be made available upon reasonable request

Locations